Trial record 1 of 1 for:    NCT01946945
Previous Study | Return to List | Next Study

Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Reprogenetics
Sponsor:
Collaborator:
Main Line Fertility Center
Information provided by (Responsible Party):
Reprogenetics
ClinicalTrials.gov Identifier:
NCT01946945
First received: August 27, 2013
Last updated: September 8, 2014
Last verified: September 2014
  Purpose

We propose to perform a clinical randomized trial to evaluate the effect of blastocyst biopsy and whole chromosome analysis by Next Generation Sequencing (NGS) in comparison to standard Assisted Reproductive Technologies (ART) methods on on implantation rates, miscarriage rates, and pregnancy rates.

This will be three studies into one: a) a comparison of treatment (NGS) and no treatment, b) a non-selection study based on the control group for which we will replace without knowing the ploidy of the embryos, but we will know it later, c) a retrospective study about the use of Mitochondrial DNA as a selection tool.


Condition Intervention Phase
Infertility
Recurrent Pregnancy Loss
Genetic: Next Generation Sequencing after Blastocyst biopsy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Screening
Official Title: Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Whole Chromosome Analysis by Next Generation Sequencing, and Replacement of a Single Euploid Embryo

Resource links provided by NLM:


Further study details as provided by Reprogenetics:

Primary Outcome Measures:
  • improvement in ongoing implantation rates [ Time Frame: When a fetal heartbeat is detected for each patient. (8 weeks after implantation). ] [ Designated as safety issue: No ]

    We foresee a significant increase in ongoing implantation rates in the Test group compared to the Control group based on several studies showing about a 50% improvement of implantation rates after Preimplantation Genetic Diagnosis (PGD) with blastocyst biopsy and comprehensive chromosome analysis techniques The center participating in the study has an average 41.5% implantation rate of blastocysts in patients 35-39 years of age without PGD. Assuming that NGS will increase the detection power of chromosome abnormalities, we expect a higher implantation rate in the test group.

    Furthermore, we expect a 6% miscarriage rate in the Test group, based on extensive data from array comparative genomic hybridization (aCGH) results (Hodes-Wertz et al. 2012), while about 21% in the Control group based on Society for Assisted Reproductive Technologies (SART) data (ages 35-40, SART 2011).



Secondary Outcome Measures:
  • Determine specificity and sensitivity rates [ Time Frame: During a pregnancy term ] [ Designated as safety issue: No ]
    The pregnancy outcome of Controls patients with euploid embryos replaced will be compared to that of control patients with aneuploid embryos replaced. This will give us the specificity of the test (false positive rate) by obtaining the ongoing pregnancy rate of cycles with aneuploid embryos replaced, and the sensitivity of the test (false negative rate) by obtaining the miscarriage rate and ongoing pregnancy rate of cycles with euploid embryos replaced.


Other Outcome Measures:
  • Correlation of Mitochondrial DNA and implantation [ Time Frame: When a fetal heartbeat is detected (8 weeks after implantation) ] [ Designated as safety issue: No ]
    The third aim of this study is to determine retrospectively if mt DNA content is linked to implantation potential and if that is measurable by NGS. NGS provides the additional advantage that it can measure mitochondrial DNA, which it's content, seems to be inversely correlated with implantation (Fragouli et al 2013, ASRM).


Estimated Enrollment: 240
Study Start Date: September 2013
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control - Standard ART treatment
Experimental: Test - PGS
All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
Genetic: Next Generation Sequencing after Blastocyst biopsy
PGD using blastocyst biopsy and testing of the biopsy by NGS
Other Name: PGD: Preimplantation Genetic Diagnosis

Detailed Description:

Patients following the inclusion criteria will be randomized into two groups:

  1. Control group: All blastocyst embryos will be biopsied on day 5/6, but the biopsies will be frozen and will not be analyzed before replacement. Blastocyst embryos will be vitrified for future frozen embryo transfer (FET) cycle. Patients will have a single hatching blastocyst (*) thawed and transferred into the uterus in a FET cycle based on standard embryo quality assessment without NGS. After transfer, all biopsied samples will be analyzed (the replaced embryo also, in order to do a non-selection study). If patients in the control group do not have a pregnancy to term from that FET cycle, euploid frozen blastocysts will be thawed and transferred on the next FET transfer.
  2. Test group: All blastocyst embryos will be biopsied on day 5/6, and the biopsies will be analyzed using NGS. (*) and Biopsied blastocyst embryos will be vitrified for a future frozen embryo transfer (FET) cycle. Patients will have a single hatching euploid blastocyst (*) thawed and transferred into the uterus in a FET cycle

(*) Hatching blastocysts as described by Gardner and Schoolcraft (1999)

The Primary efficacy endpoint of comparing the study group with the control will be ongoing implantation rate (# fetus reaching 2nd trimester / # embryos replaced).

All biopsied embryos from the test and control group will have their mitochondrial DNA analyzed, but that information will not be used for purposes of choosing embryos for replacement. Retrospectively but blindly (see blinding of results section), the information will be used at the end of the study to determine which embryos have a higher chance of implanting. If at that point the participating patients have remaining embryos frozen, they will be able to use that information for purposes of embryo selection.

  Eligibility

Ages Eligible for Study:   18 Years to 42 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients medically cleared to do a fresh or frozen embryo transfer.
  • Age up to 42 years

Exclusion Criteria:

  • microsurgical epididymal sperm aspiration (MESA) and Testicular sperm extraction (TESE) patients
  • At least one partner carrier of a chromosomal or genetic disease
  • Abnormal ovarian reserve, defined as follicle stimulating hormone (FSH) of >10 IU/L on day 2-4 of the cycle and anti-mullerian hormone (AMH) < 1ng /ml (If only one of the two parameters altered then patients is acceptable). This is based on Mandy Katz abstract at American Society for Reproductive Medicine (ASRM) 2011 where they showed that these patients have 35% chance of having no euploid embryos - They are excluded only to make the study size smaller, otherwise, if an euploid embryo is found in these patients, they implant as well as patients with normal ovarian reserve. Not all centers do AMH testing - we recommend first to run FSH and only test AMH if FSH is abnormal.
  • Egg donor cycle (sperm donor is acceptable)
  • Gender selection cycles
  • Thaw cycles
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01946945

Locations
United States, New Jersey
Reprogenetics Recruiting
Livingston, New Jersey, United States, 07039
Contact: Allen Kung, BSc    973-758-7970    akung@reprogenetics.com   
Principal Investigator: Santiago Munne, Ph.D         
Sponsors and Collaborators
Reprogenetics
Main Line Fertility Center
Investigators
Study Director: Santiago Munne, PhD Reprogenetics
  More Information

Publications:
Forman EJ, Hong KH, Ferry KM, Tao X, Taylor D, Levy B, Treff NR, Scott RT (2013) In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial, Fertil Steril, in press (doi:10.1016/j.fertnstert.2013.02.056)
Gardner DK and Schoolcraft WB. In vitro culture of human blastocysts. In: Jansen R, Mortimer D. eds. Towards Reproductive Certainty: Fertility and Genetics Beyond 1999. Carnforth, Parthenon Publishin, 1999, 378-88
Scott RT, Ferry KM, Su J, Tao X, Scott K, Treff NR (2012) Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertil Steril, 2012, 97:870-875 (doi:10.1016/j.fertnstert.2012.01.104

Responsible Party: Reprogenetics
ClinicalTrials.gov Identifier: NCT01946945     History of Changes
Other Study ID Numbers: Reprogenetics-3.109
Study First Received: August 27, 2013
Last Updated: September 8, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Reprogenetics:
infertility
recurrent pregnancy loss
miscarriage
Next Generation Sequencing

Additional relevant MeSH terms:
Infertility
Genital Diseases, Female
Genital Diseases, Male

ClinicalTrials.gov processed this record on October 29, 2014